- Home
- VNT vs PCVX Comparison
VNT vs PCVX Comparison
Compare VNT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNT | PCVX |
|---|---|---|
| Founded | 2019 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | VNT | PCVX |
|---|---|---|
| Price | $37.33 | $45.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $46.11 | ★ $105.00 |
| AVG Volume (30 Days) | 925.4K | ★ 1.1M |
| Earning Date | 02-12-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $3,043,900,000.00 | N/A |
| Revenue This Year | $2.79 | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $27.22 | $27.66 |
| 52 Week High | $43.88 | $93.77 |
Technical Indicators
Market Signals| Indicator | VNT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 43.42 | 49.23 |
| Support Level | $38.20 | $44.57 |
| Resistance Level | $39.02 | $48.93 |
| Average True Range (ATR) | 0.82 | 2.14 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 9.96 | 36.66 |
Price Performance
Historical ComparisonAbout VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.